NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...
Purple Biotech (PPBT) announced that the U.S. Patent and Trademark Office has issued a patent for NT219 used in combination with epidermal ...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
The U.S. Patent and Trademark Office issued a patent for NT219 used in combination with EGFR antibodies for treating cancer patients who have acquired resistance to EGFR therapies. This latest U.S ...
Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings ...
Bicara Therapeutics Inc.’s BCAX share price has dipped by 10.28%, which has investors questioning if this is right time to ...
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and ...
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March ...
REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback